Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open-Label Trial in Patients With Stage IV Malignant Melanoma Using Melaxin as a Cancer Vaccine in Conjunction With BCG

NCT00671554 is registered in ClinicalTrials.gov with Prisma Health-Upstate as lead sponsor.

NCT NCT00671554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00671554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open-Label Trial in Patients With Stage IV Malignant Melanoma Using Melaxin as a Cancer Vaccine in Conjunction With BCG
Lead sponsor
Prisma Health-Upstate
Phase
Phase 1/2
Overall status
Terminated
Start date
April 30, 2008
Completion date
March 31, 2009
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma